KCA
NKTR icon

KVP Capital Advisors’s Nektar Therapeutics NKTR Stock Holding History

KVP Capital Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.88M Hold
26,900
– – 1.38% 29
2026
Q1 		$1.94M Hold
26,900
– – 1.45% 27
2025
Q4 		$1.14M Buy
+26,900
New +$1.51M 1.1% 23

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KVP Capital Advisors's NKTR Position: Q2 2026 in Review

KVP Capital Advisors held its Nektar Therapeutics (NKTR) position steady in Q2 2026 at 26,900 shares worth $1.88M. The position accounts for 1.38% of the portfolio, ranked #29.

KVP Capital Advisors first reported a position in NKTR in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.94M in Q1 2026. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • KVP Capital Advisors held 26,900 shares of Nektar Therapeutics worth $1.88M as of Q2 2026.
  • KVP Capital Advisors left its Nektar Therapeutics share count unchanged in Q2 2026.
  • Nektar Therapeutics made up 1.38% of KVP Capital Advisors's portfolio in Q2 2026, its #29 holding.
  • KVP Capital Advisors first reported a position in Nektar Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • KVP Capital Advisors's Nektar Therapeutics position peaked at $1.94M in Q1 2026.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on KVP Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.